Q&A Case studySterile Manufacturing
Closing the Annex 1 Gap on a Legacy Fill-Finish Line
How Biocon Biologics retrofitted a 2011-vintage vial line to satisfy the revised Annex 1 contamination control strategy without a full facility rebuild.
Reduction in manual interventions per batch
58%
The practitioner
Dr. Meera Iyer
VP Manufacturing Operations, Biocon Biologics
Interview by Mrudula Kulkarni
Managing Editor - Pharma Now
14 Jul 2026 · 9 min read
The challenge
The Bengaluru site was operating a legacy vial fill line with an open RABS design that predated the revised Annex 1.
The approach
The team ran a structured contamination risk map across the twelve gaps, then converged on a phased retrofit: closed RABS gloves…
The result
Twelve months in, the line passed a pre-approval inspection with zero Annex 1 observations.
The challenge
The Bengaluru site was operating a legacy vial fill line with an open RABS design that predated the revised Annex 1. An internal audit in early 2024 identified twelve control-strategy gaps ranging from personnel intervention frequency to viable EM trending, and a full line replacement was estimated at 28 months and USD 34 million.
The approach
The team ran a structured contamination risk map across the twelve gaps, then converged on a phased retrofit: closed RABS gloves, redesigned intervention SOPs, and a rebuilt EM programme with rapid microbial methods on the highest-risk points. A written contamination control strategy narrative was drafted in parallel and reviewed against three anonymised inspector observation letters.
The result
Twelve months in, the line passed a pre-approval inspection with zero Annex 1 observations. Intervention frequency dropped by more than half, viable EM excursions fell into single digits per quarter, and total capital spend came in at roughly a quarter of the greenfield estimate.
Q
What made you choose retrofit over a full line rebuild?
The math was simple. A greenfield line was quoted at 28 months and USD 34 million, and we had a pre-approval inspection window that closed 12 months out.
Retrofit let us keep the existing shell of the room and focus capital on the specific contamination-control gaps the audit had flagged. It also meant we could keep the line producing during construction — critical for supply continuity on a shortage-list product.
Q
Where did the biggest reduction in intervention frequency come from?
Glove redesign accounted for roughly two-thirds of it. The original RABS gloves required a full operator arm-in intervention for every stopper transfer; the redesigned assembly moved that to a semi-automated pass-through with a hand-only correction step.
The rebuilt EM programme surfaced the other third — we caught trend deviations earlier, which meant we corrected process parameters before they triggered an intervention.
Q
What advice would you give a site starting this journey now?
Write the contamination control strategy narrative first, not last. Ours was the anchor document — everything from SOP redesign to EM sampling plans traced back to a specific paragraph in the CCS.
And review it against real observation letters, not just the guidance. The letters teach you what inspectors actually look at when they walk the line.
A greenfield line would have taken 28 months. We had one PAI on the calendar in 12.
Dr. Meera Iyer, VP Manufacturing Operations
Measured impact
58%
Reduction in manual interventions per batch
0
Annex 1 observations at PAI
73%
Capital saved vs greenfield line
The method, in brief
1
Map the twelve gaps against real observation letters — Started with three anonymised FDA warning letters and mapped each cited observation to the twelve gaps the internal audit had raised. Prioritised the ones that overlapped with recent inspector citations.
2
Draft the contamination control strategy narrative first — Wrote the CCS document as the anchor for every downstream change. Every SOP revision, EM sample plan, and equipment change referenced a specific paragraph in the CCS.
3
Redesign gloves + interventions before touching equipment — Ordered replacement RABS glove assemblies and rewrote intervention SOPs in parallel. Ran a two-week operator training programme before any hardware change hit the floor.
4
Rebuild the EM programme with rapid microbial methods — Added rapid microbial methods on the highest-risk sample points, and rewired trend analysis to flag drift within a shift rather than a batch. Trained microbiology and QA together on the new triage workflow.
5
Dry-run the PAI internally, then close on time — Ran a full internal mock inspection in month 10, tightened the last three findings in month 11, and closed the real PAI with zero Annex 1 observations in month 12.
More case studies
All case studies
Q&AQuality 4.0
A Quality 4.0 Analytics Layer Above Legacy LIMS and MES
47%Fewer trend-triggered investigations year on year
8 min
Q&AContinuous Manufacturing
From Batch to Continuous: Rewiring an OSD Product for Steady-State Manufacture
38%Reduction in end-to-end cycle time
11 min
Q&ADigital Batch Records
Retiring Paper Batch Records Across a Commercial Biologics Campus
85%Reduction in batch review lead time
10 minHave a result worth sharing?
Pitch a case study from your site.
If you have changed a method and have the data to show for it, our editors would like to hear from you — in confidence, with no obligation to publish.
Discussion